New combo therapy aims to shrink rectal tumors before surgery
NCT ID NCT07580339
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding an experimental drug called DCSZ11 to standard radiation and chemotherapy can improve outcomes for people with a high-risk type of rectal cancer. The study will enroll 30 adults who have not had prior treatment. The goal is to see if the combination leads to a complete disappearance of the tumor before surgery, either through pathology or imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DCSZ11 (a CD93 inhibitor) combined with radiation and capecitabine/oxaliplatin chemotherapy
What this could lead to
If successful, this combination could increase the chance of eliminating the tumor before surgery, potentially allowing some patients to avoid surgery altogether.
What could go wrong
This is a small, early-phase trial with only 30 participants. The drug combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins SKCCC
Baltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact